432 related articles for article (PubMed ID: 22290531)
1. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.
Sun CC; Vaja V; Babitt JL; Lin HY
Am J Hematol; 2012 Apr; 87(4):392-400. PubMed ID: 22290531
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.
Theurl I; Schroll A; Sonnweber T; Nairz M; Theurl M; Willenbacher W; Eller K; Wolf D; Seifert M; Sun CC; Babitt JL; Hong CC; Menhall T; Gearing P; Lin HY; Weiss G
Blood; 2011 Nov; 118(18):4977-84. PubMed ID: 21730356
[TBL] [Abstract][Full Text] [Related]
3. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
[TBL] [Abstract][Full Text] [Related]
4. Regulation of hepcidin and iron-overload disease.
Lee PL; Beutler E
Annu Rev Pathol; 2009; 4():489-515. PubMed ID: 19400694
[TBL] [Abstract][Full Text] [Related]
5. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation.
Langer AL; Ginzburg YZ
Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S37-S46. PubMed ID: 28328181
[TBL] [Abstract][Full Text] [Related]
6. A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease.
Petzer V; Tymoszuk P; Asshoff M; Carvalho J; Papworth J; Deantonio C; Bayliss L; Wake MS; Seifert M; Brigo N; Valente de Souza L; Hilbe R; Grubwieser P; Demetz E; Dichtl S; Volani C; Berger S; Böhm F; Hoffmann A; Pfeifhofer-Obermair C; von Raffay L; Sopper S; Arndt S; Bosserhoff A; Kautz L; Perrier P; Nairz M; Wolf D; Weiss G; Germaschewski V; Theurl I
Blood; 2020 Aug; 136(9):1080-1090. PubMed ID: 32438400
[TBL] [Abstract][Full Text] [Related]
7. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.
Theurl I; Aigner E; Theurl M; Nairz M; Seifert M; Schroll A; Sonnweber T; Eberwein L; Witcher DR; Murphy AT; Wroblewski VJ; Wurz E; Datz C; Weiss G
Blood; 2009 May; 113(21):5277-86. PubMed ID: 19293425
[TBL] [Abstract][Full Text] [Related]
8. Iron sequestration and anemia of inflammation.
Ganz T; Nemeth E
Semin Hematol; 2009 Oct; 46(4):387-93. PubMed ID: 19786207
[TBL] [Abstract][Full Text] [Related]
9. Iron regulation by hepcidin.
Zhao N; Zhang AS; Enns CA
J Clin Invest; 2013 Jun; 123(6):2337-43. PubMed ID: 23722909
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin and disorders of iron metabolism.
Ganz T; Nemeth E
Annu Rev Med; 2011; 62():347-60. PubMed ID: 20887198
[TBL] [Abstract][Full Text] [Related]
11. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia.
Lasocki S; Millot S; Andrieu V; Lettéron P; Pilard N; Muzeau F; Thibaudeau O; Montravers P; Beaumont C
Crit Care Med; 2008 Aug; 36(8):2388-94. PubMed ID: 18664788
[TBL] [Abstract][Full Text] [Related]
12. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.
Ganz T; Nemeth E
Hematology Am Soc Hematol Educ Program; 2011; 2011():538-42. PubMed ID: 22160086
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening of small molecules identifies hepcidin antagonists.
Fung E; Sugianto P; Hsu J; Damoiseaux R; Ganz T; Nemeth E
Mol Pharmacol; 2013 Mar; 83(3):681-90. PubMed ID: 23292796
[TBL] [Abstract][Full Text] [Related]
14. Hepcidin, the iron watcher.
Viatte L; Vaulont S
Biochimie; 2009 Oct; 91(10):1223-8. PubMed ID: 19555735
[TBL] [Abstract][Full Text] [Related]
15. Autocrine formation of hepcidin induces iron retention in human monocytes.
Theurl I; Theurl M; Seifert M; Mair S; Nairz M; Rumpold H; Zoller H; Bellmann-Weiler R; Niederegger H; Talasz H; Weiss G
Blood; 2008 Feb; 111(4):2392-9. PubMed ID: 18073346
[TBL] [Abstract][Full Text] [Related]
16. The regulation of hepcidin and its effects on systemic and cellular iron metabolism.
Fleming MD
Hematology Am Soc Hematol Educ Program; 2008; ():151-8. PubMed ID: 19074074
[TBL] [Abstract][Full Text] [Related]
17. Anemia of chronic disease.
Gangat N; Wolanskyj AP
Semin Hematol; 2013 Jul; 50(3):232-8. PubMed ID: 23953340
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease.
Malyszko J; Malyszko JS; Matuszkiewicz-Rowinska J
Expert Opin Ther Targets; 2019 May; 23(5):407-421. PubMed ID: 30907175
[TBL] [Abstract][Full Text] [Related]
19. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease.
Wang L; Trebicka E; Fu Y; Ellenbogen S; Hong CC; Babitt JL; Lin HY; Cherayil BJ
Inflamm Bowel Dis; 2012 Jan; 18(1):112-9. PubMed ID: 21351217
[TBL] [Abstract][Full Text] [Related]
20. Advancements in anemias related to chronic conditions.
Guidi GC; Lechi Santonastaso C
Clin Chem Lab Med; 2010 Sep; 48(9):1217-26. PubMed ID: 20618092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
